UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 365,304 Shares of Krystal Biotech, Inc. $KRYS

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 173.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 575,506 shares of the company’s stock after purchasing an additional 365,304 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 1.99% of Krystal Biotech worth $103,764,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Ameriprise Financial Inc. increased its stake in shares of Krystal Biotech by 26.4% in the fourth quarter. Ameriprise Financial Inc. now owns 113,476 shares of the company’s stock valued at $17,779,000 after buying an additional 23,727 shares during the period. Deutsche Bank AG increased its stake in shares of Krystal Biotech by 62.5% in the fourth quarter. Deutsche Bank AG now owns 25,361 shares of the company’s stock valued at $3,973,000 after buying an additional 9,750 shares during the period. Janus Henderson Group PLC increased its stake in shares of Krystal Biotech by 16.1% in the fourth quarter. Janus Henderson Group PLC now owns 10,071 shares of the company’s stock valued at $1,579,000 after buying an additional 1,400 shares during the period. ProShare Advisors LLC increased its stake in shares of Krystal Biotech by 28.6% in the fourth quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock valued at $1,386,000 after buying an additional 1,967 shares during the period. Finally, Soleus Capital Management L.P. increased its stake in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after buying an additional 141,400 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the sale, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 49,800 shares of company stock valued at $7,487,943. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $143.68 on Friday. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of 29.20 and a beta of 0.66. The business’s fifty day moving average is $146.81 and its 200 day moving average is $152.58.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million during the quarter, compared to analysts’ expectations of $95.42 million. Equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

KRYS has been the subject of a number of research analyst reports. Citigroup reiterated a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Bank of America reduced their price objective on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, August 22nd. Finally, Chardan Capital reduced their price objective on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $209.00.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).